Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:Q8NEX9 (
reductase
)
26,410
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We previously reported the cloning of a human liver leukotriene B(4) (LTB(4)) omega-hydroxylase P450 designated CYP 4F2 [Kikuta et al. (1994) FEBS Lett. 348, 70-74]. However, the properties of CYP 4F2 remain poorly defined. The preparation solubilized using n-octyl-beta-D-glucopyranoside from microsomes of CYP 4F2-expressing yeast cells catalyzes v- hydroxylation of LTB(4), 6-trans-LTB(4), lipoxin A(4), 8-hydroxyeicosatetraenoate, 12-hydroxyeicosatetraenoate, and 12-hydroxystearate in the presence of rabbit liver NADPH-P450
reductase
. In addition, the enzyme shows ethoxycoumarin O-deethylase and p-nitroanisole O-demethylase activities. The enzyme was purified to apparent electrophoretic homogeneity from yeast cells by sequential chromatography of solubilized microsomes through amino-n-hexyl-Sepharose 4B, DEAE-HPLC, and hydroxylapatite HPLC columns. The final preparation showed a specific content of 11.1 nmol of P450/mg of protein, with an apparent molecular mass of 56.3 kDa. CYP 4F2 was distinguished from the closely homologous CYP 4F3 (human neutrophil
LTB(4) omega-hydroxylase
) by its much higher K(m) for LTB(4), inability to omega-hydroxylate lipoxin B(4), and extreme instability.
...
PMID:Characterization of human liver leukotriene B(4) omega-hydroxylase P450 (CYP4F2). 1083 73
Cytochrome P-450 CYP4F3A catalyzes the inactivation of leukotriene B(4) by omega-hydroxylation, an activity of which is specifically expressed in human neutrophils. Here, we examined expression of the LTB(4) omega-hydroxylating activity during the differentiation of HL60 cells, an acute promyelocytic leukemia cell line, in the presence of various inducers. Among the inducers used, all-trans-retinoic acid (ATRA) most strongly induces the LTB(4) omega-hydroxylating activity in a dose-dependent manner. The time course of the induction of the omega-hydroxylating activity correlates well with that of the superoxide-generating activity, indicative of cell differentiation. ATRA-treated cell microsomes convert LTB(4) to its 20-hydroxyl derivative under aerobic conditions in the present of NADPH. The reaction is inhibited by carbon monoxide, an inhibitor of cytochrome P-450, and by antibodies raised against NADPH-P-450
reductase
. CYP4F3A appears to be responsible for the
LTB(4) omega-hydroxylase
activity, based on the following observations: expression of the mRNA for CYP4F3A is observed together with the induction of LTB(4) omega-hydroxylating activity in ATRA-treated HL60 cells; and the apparent K(m) values for the omega-hydroxylation of LTB(4) and lipoxin B(4) by ATRA-treated cell microsomes are essentially the same as those of CYP4F3A in human neutrophil microsomes.
...
PMID:Induction of cytochrome CYP4F3A in all-trans-retinoic acid-treated HL60 cells. 1471 52